Investors interested in stocks from the Medical - Products sector have probably already heard of Smith & Nephew (SNN) and EssilorLuxottica Unsponsored ADR (ESLOY). But which of these two stocks is more attractive to value investors?

Investors looking for stocks in the Financial - Investment Management sector might want to consider either AllianceBernstein (AB) or Cohen & Steers Inc (CNS). But which of these two stocks presents investors with the better value opportunity right now?

Investors looking for stocks in the Financial - Miscellaneous Services sector might want to consider either XP Inc.A (XP) or SoFi Technologies, Inc. (SOFI). But which of these two companies is the best option for those looking for undervalued stocks?

Investors with an interest in Broadcast Radio and Television stocks have likely encountered both Fox Corporation (FOX) and Netflix (NFLX). But which of these two stocks presents investors with the better value opportunity right now?

NEE rides Florida's population and job growth to boost demand, add customers and grow earnings in a pro-utility climate.

AMT is likely to gain from the solid demand for wireless connectivity and capital allocation strategy despite customer concentration and consolidation.

CCJ lifts Q1 uranium output by 3% and holds firm on 2025 outlook despite JV Inkai's temporary shutdown.

Apartment demand surges in Q2, boosting occupancy and stability for residential REITs like AVB, EQR, ESS and UDR.

C is set to report Q2 results with projected y/y revenue and earnings growth, but will rising credit costs weigh on performance? Let us find out.

U.S. equities were lower at midday after President Donald Trump made more tariff announcements. The Dow Jones Industrial Average, S&P 500, and Nasdaq all declined.

CrowdStrike Holdings Inc. NASDAQ: CRWD is one of the best-performing technology stocks of 2025, with shares up 50% year-to-date. That rally reflects renewed investor confidence in its Falcon platform, which is a true comeback story following the high-profile service outage in 2024.

It's been an eventful week for the EV maker. Transcript: It was an eventful - and rocky - week for Tesla.

Neils Christensen has a diploma in journalism from Lethbridge College and has more than a decade of reporting experience working for news organizations throughout Canada. His experiences include covering territorial and federal politics in Nunavut, Canada.

FHLC is a solid healthcare ETF, but VHT offers slightly better performance, liquidity, and diversification for a similar expense ratio. FHLC's high concentration in top holdings and lower trading volume raise concerns compared to VHT's broader portfolio and superior liquidity. Healthcare sector tailwinds like innovation, aging demographics, and biotech growth benefit all major ETFs, but VHT stands out on key metrics.

GRPN and CARG look good in an attractively valued ecommerce industry, fueled by Gen-Z, AI and the rise of social shopping trends.

Oracle (ORCL) reported earnings 30 days ago. What's next for the stock?

Smucker (SJM) reported earnings 30 days ago. What's next for the stock?

DALLAS--(BUSINESS WIRE)--Flowserve Corporation (NYSE:FLS) (“Flowserve” or the “Company”), a leading provider of flow control products and services for the global infrastructure markets, will issue its second quarter 2025 earnings release after the close of the New York Stock Exchange (NYSE) on Wednesday, July 30. Flowserve will host a conference call to discuss second quarter results the following morning, on Thursday, July 31, at 10:00 a.m. Eastern Time. The earnings materials and webcast of t.

WASHINGTON--(BUSINESS WIRE)--Teledyne FLIR Defense, part of Teledyne Technologies Incorporated (NYSE:TDY), has made the following statement in regard to U.S. Secretary of Defense Pete Hegseth's ‘Unleashing U.S. Military Drone Dominance' memo of July 10. “Teledyne FLIR Defense readily supports U.S. Department of Defense efforts to bolster our drone readiness and ensure all our warfighters are equipped with the right drone systems, technology, and training to achieve success on the battlefield,”.

Novartis cannot block drugmaker MSN Pharmaceuticals from launching a generic version of its blockbuster heart-failure drug Entresto through late 2026, a Delaware federal judge said on Friday.